Axsome Therapeutics, Inc. 4

CEO Herriot Tabuteau exercised expiring stock options and sold 49,664 Axsome Therapeutics (AXSM) shares for about $10.8 million in early August 2026 under a 10b5-1 plan.

On August 5–6, 2026, Axsome Therapeutics CEO Herriot Tabuteau executed expiring stock options and immediately sold the underlying shares pursuant to a completed Rule 10b5-1 trading plan. He exercised 45,004 options at $4.95 on August 5 and 4,660 options at $4.95 on August 6, then sold all 45,004 shares at a weighted average of $212.01 on August 5 and all 4,660 shares at a weighted average of $213.95 on August 6 in open market transactions, generating aggregate sale proceeds of roughly $10.8 million. These were characterized as necessary exercises due to the 10-year option expiration, followed by corresponding sales of the acquired shares, leaving him with 7,229 shares of common stock held directly and an additional 7,344,500 shares held indirectly through an entity over which he has voting and dispositive power.

Filing Facts

CIK

1579428

Ticker

AXSM

Form

4

Source Type

fda

Accession

0001193125-26-340688

Alert Tier

6